logo
National chicken rental business brings birds to VT backyards

National chicken rental business brings birds to VT backyards

Yahoo26-02-2025

GREENSBORO, Vt. (ABC22 FOX44) – Laura Hill loves chickens, but never imagined she'd be renting them to strangers.
Five years ago, Hill's 14-year-old son Warren connected with the owner of 'Rent the Chicken,' a growing national program dedicated to the rental chicken business. Hill says her son fell in love with the idea of running his own business, which now supplies chickens across Northeast Vermont to over two dozen renters. Now in college, she says, he manages the deliveries when he comes home for school breaks.
'I really like chickens and agriculture, it's just part of our life and so it's fun to just share it with other people,' said Hill.
With about 70 chickens currently on the property, Hill says she is preparing for an influx of web orders in the next month. Renters, who can choose between adopting two to four chickens for the summer, also receive a portable chicken coop, feed, water and food dishes and instructions on how to care for the birds.
Hill says, while her backyard flock has not been affected by the growing number of avian flu cases this season, she will be reminding renters to take precautions, which includes changing shoes and keeping the birds close to home.
'You could pick up something from another farm or property and bring it into your flock,' she said.
Natalie, Hill's teenage daughter, says while she helps out with the chickens, she prefers the company of her cows which she enters in contests across New England. Her lack of chicken love, she says, comes from her big brother's insistence that she's better at chasing down the feistier fowl.
'He says it's because I can run faster, but I think it's more that he doesn't want to,' she said with a laugh.
The chickens will be delivered to their part-time owners starting in May and will come back to Hill's care in October. But if owners fall in with their chickens, she says, they always have the option to permanently adopt their feathered friends.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Premium brand pet food plant opens in Rockingham County
Premium brand pet food plant opens in Rockingham County

Yahoo

time12 minutes ago

  • Yahoo

Premium brand pet food plant opens in Rockingham County

ROCKINGHAM COUNTY, N.C. (WGHP) — A premium brand pet food plant is coming to the Triad all the way from Italy. Farmina Pet Foods will be opening its first-ever U.S. manufacturing plant in Rockingham County. It's a major investment for the region. FPF's owner and CEO, Dr. Angelo Russo, said that it was North Carolina's hospitality, good conditions for economic growth and an abundance of qualified workers that stood out to them. For Rockingham County, it will bring up to 300 more jobs and technologies from around the world. North Carolina Senator Phil Berger said now is a fascinating time for the pet industry. 'Fewer people are having kids, but … more getting dogs … and cats. I don't want to forget about our feline friends, but it's something people care a great deal about,' Berger said. Berger described FPF as one of the most reputable pet food brands that will bring a lot of growth to the local economy. 'Good, high-paying manufacturing jobs. Great for Rockingham County,' he said. In Reidsville, FPF will be opening its first U.S. manufacturing facility, and they have ambitious plans to deliver the best quality pet foods. FPF's North America CEO, Loris Rinaldi, said it was a $115 million investment. He is confident that it will be worth it for both the company and the county. 'This facility is designed to expand and have three times the production capacity we have today, and that additional investment is for the 300 people that will run this facility 24/7,' Rinaldi said. The facility will run with some cutting-edge technology. 'All of our bags are packed with nitrogen, which keeps everything fresh until you open the bag,' Rinaldi said. After having facilities in Italy and South America, this would be FPF's fifth facility, and they could not have found a better place to start off their North American venture. 'Your kind welcome … Economically speaking, the good conditions you give to us and a lot of qualified workers,' Russo said. Russo said this is just the beginning of the journey. According to Rinaldi, they will import machines from Japan, Italy and France for their technology. FPF's production will begin in July. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James
Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James

Yahoo

time17 minutes ago

  • Yahoo

Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James

Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the 13 Biotech Stocks with Huge Upside Potential. Raymond James has started coverage of Avidity Biosciences, Inc. (NASDAQ:RNA), with a Strong Buy rating and a price objective of $65. A scientist holding a vial of a promising product candidate for therapeutic development. The rating is part of a larger biotech sector note, in which the firm sees favorable risk/reward across the board. Raymond James points out that less de-risked platforms can produce the most outsized returns, even if companies with de-risked, high probability-of-success assets are frequently viewed with greater certainty. The firm stresses its confidence in del-zota, which is anticipated to be the first medicine from Avidity Biosciences, Inc. (NASDAQ:RNA)'s antibody oligonucleotide conjugate (AOC) platform to be approved. Avidity Biosciences, Inc. (NASDAQ:RNA) is becoming more well-known for its AOC platform, which targets muscle disorders by combining oligonucleotides and antibodies. According to Raymond James, one of the platform's top candidates, Del-Zota, has a strong chance of being approved. The $65 objective is in line with the firm's opinion that early-stage, less-risked assets can yield higher returns and points out faith in the platform's revolutionary potential. Avidity Biosciences, Inc. (NASDAQ:RNA) is a biopharmaceutical firm dedicated to developing a novel type of RNA treatment known as Antibody Oligonucleotide Conjugates, or AOCs. While we acknowledge the potential of RNA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None.

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

Yahoo

time19 minutes ago

  • Yahoo

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, announced today that members of its senior management team will present and participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11th at 10:00 am ET. A live webcast of the presentation can be accessed through the Investors section of the Company's website at Following the live presentation, a replay of the webcast will be available on the Company's website following the presentation date. About Lyell Immunopharma, Inc. Lyell is a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. To realize the potential of cell therapy for cancer, Lyell utilizes a suite of technologies to endow CAR T cells with attributes needed to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical responses, including the ability to resist exhaustion, maintain qualities of durable stemness and function in the hostile tumor microenvironment. To learn more, please visit Contact: Ellen RoseSenior Vice President, Communications and Investor Relationserose@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store